1 FEV1 (% predicted) |
7 |
197 |
Mean Difference (IV, Fixed, 95% CI) |
‐3.65 [‐7.22, ‐0.08] |
1.1 Mild |
5 |
129 |
Mean Difference (IV, Fixed, 95% CI) |
‐4.09 [‐8.14, ‐0.03] |
1.2 Mild to moderate |
2 |
68 |
Mean Difference (IV, Fixed, 95% CI) |
‐2.17 [‐9.65, 5.31] |
1.3 Moderate |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
1.4 Moderate to severe |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
2 FEV1 (litres) |
4 |
103 |
Mean Difference (IV, Fixed, 95% CI) |
0.07 [‐0.25, 0.40] |
2.1 Mild |
2 |
47 |
Mean Difference (IV, Fixed, 95% CI) |
0.14 [‐0.27, 0.55] |
2.2 Mild to moderate |
1 |
26 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.38 [‐1.08, 0.32] |
2.3 Moderate |
1 |
30 |
Mean Difference (IV, Fixed, 95% CI) |
0.41 [‐0.40, 1.22] |
2.4 Moderate to severe |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
3 Change in FEV1 (litres) compared to baseline |
2 |
99 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.20 [‐0.33, ‐0.07] |
3.1 Mild |
2 |
99 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.20 [‐0.33, ‐0.07] |
3.2 Mild to moderate |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
3.3 Moderate |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
3.4 Moderate to severe |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
4 Morning PEFR (L/min) |
2 |
77 |
Mean Difference (IV, Fixed, 95% CI) |
‐31.22 [‐71.25, 8.80] |
4.1 Mild |
1 |
31 |
Mean Difference (IV, Fixed, 95% CI) |
‐28.0 [‐86.82, 30.82] |
4.2 Mild to moderate |
1 |
46 |
Mean Difference (IV, Fixed, 95% CI) |
‐34.0 [‐88.62, 20.62] |
4.3 Moderate |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
4.4 Moderate to severe |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
5 Change in morning PEFR (L/min) compared to baseline |
6 |
469 |
Mean Difference (IV, Fixed, 95% CI) |
‐28.92 [‐36.11, ‐21.74] |
5.1 Mild |
4 |
259 |
Mean Difference (IV, Fixed, 95% CI) |
‐30.91 [‐39.50, ‐22.32] |
5.2 Mild to moderate |
2 |
210 |
Mean Difference (IV, Fixed, 95% CI) |
‐24.28 [‐37.41, ‐11.15] |
5.3 Moderate |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
5.4 Moderate to severe |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
6 Change in evening PEFR (L/min) compared to baseline |
6 |
469 |
Mean Difference (IV, Fixed, 95% CI) |
‐20.64 [‐28.29, ‐13.00] |
6.1 Mild |
4 |
259 |
Mean Difference (IV, Fixed, 95% CI) |
‐18.39 [‐27.60, ‐9.19] |
6.2 Mild to moderate |
2 |
210 |
Mean Difference (IV, Fixed, 95% CI) |
‐25.65 [‐39.38, ‐11.93] |
6.3 Moderate |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
6.4 Moderate to severe |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
7 Change in daytime use of short‐acting beta2 agonist (puffs/daytime) compared to baseline |
5 |
480 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.43 [‐0.80, ‐0.06] |
7.1 Mild |
4 |
311 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.49 [‐0.95, ‐0.04] |
7.2 Mild to moderate |
1 |
169 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.32 [‐0.93, 0.29] |
7.3 Moderate |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
7.4 Moderate to severe |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
8 Change in night‐time use of short‐acting beta2 agonist compared to baseline (puffs/night) |
3 |
304 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.71 [‐1.09, ‐0.33] |
8.1 Mild |
2 |
133 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.96 [‐1.67, ‐0.24] |
8.2 Mild to moderate |
1 |
171 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.61 [‐1.06, ‐0.16] |
8.3 Moderate |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
8.4 Moderate to severe |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
9 Methacholine bronchial responsiveness (log 10 values) |
3 |
76 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.04 [‐0.29, 0.21] |
9.1 Mild |
2 |
54 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.12 [‐0.48, 0.23] |
9.2 Mild to moderate |
1 |
22 |
Mean Difference (IV, Fixed, 95% CI) |
0.04 [‐0.31, 0.39] |
9.3 Moderate |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
9.4 Moderate to severe |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
10 Histamine bronchial responsiveness (log 10 values) |
2 |
80 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.40 [‐0.70, ‐0.11] |
10.1 Mild |
1 |
31 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.40 [‐0.70, ‐0.10] |
10.2 Mild to moderate |
1 |
49 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.53 [‐2.75, 1.69] |
10.3 Moderate |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
10.4 Moderate to severe |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
11 Withdrawal due to asthma exacerbation (No. of patients) |
17 |
910 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.17 [0.09, 0.33] |
11.1 Mild |
12 |
520 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.32 [0.13, 0.81] |
11.2 Mild to moderate |
4 |
366 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.11 [0.04, 0.28] |
11.3 Moderate |
1 |
24 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
11.4 Moderate to severe |
0 |
0 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
12 Requirement for one or more courses of oral steroid for asthma exacerbation (No. of patients) |
5 |
255 |
Peto Odds Ratio (Peto, Fixed, 95% CI) |
0.25 [0.13, 0.48] |
12.1 Mild |
3 |
109 |
Peto Odds Ratio (Peto, Fixed, 95% CI) |
0.38 [0.13, 1.13] |
12.2 Mild to moderate |
2 |
146 |
Peto Odds Ratio (Peto, Fixed, 95% CI) |
0.20 [0.09, 0.44] |
12.3 Moderate |
0 |
0 |
Peto Odds Ratio (Peto, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
12.4 Moderate to severe |
0 |
0 |
Peto Odds Ratio (Peto, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
13 Oropharyngeal side effects (No. of patients) |
5 |
275 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.81 [0.53, 1.23] |
13.1 Mild |
4 |
159 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.26 [0.69, 2.31] |
13.2 Mild to moderate |
1 |
116 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.55 [0.30, 1.00] |
13.3 Moderate |
0 |
0 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
13.4 Moderate to severe |
0 |
0 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |